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The goal of this research was to use a distal signaling pathway analysis to 
evaluate the extent of agonist independent constitutive signaling among orphan class-A G 
protein coupled receptors (GPCRs).  These receptors translate extracellular signals via 
conformational change into intracellular activation of different G proteins and subsequent 
second messenger synthesis.  These small molecules regulate cellular biochemistry, 
eventually leading to nuclear signaling that results in changes in gene expression. Some 
GPCRs are capable of signaling in the absence of an activating ligand, a phenomenon 
called constitutive activity that is inhibited via an “inverse-agonist”.  The use of cAMP 
dependent Luciferase expression is used to compare the canonical signaling of all five 
wild-type Muscarinic Acetylcholine receptors and their constitutively active (CA) mutant 
counterparts.  All five members, both wild-type and CA, signaled via cAMP dependent 
pathways, although only the CA mutants do so in the absence of an agonist.  This 
technique is then applied to 40 different orphan GPCRs for which an agonist is 
unknown/not-present. This resulted in 75% (30 out of 40) scoring as constitutively active, 
grouped into five different categories based on their response.  The largest and most 
significant group of 17 orphans inhibited cAMP dependent expression, both basal and 
forskolin stimulated, by more than 40%, indicating activation of Gαi.  In total, novel 
findings of constitutive activity were found in 23 of the 40 Orphan receptors with results 
otherwise in agreement with literature in most cases.  Orphan receptors that were closely 
related based on amino acid homology tended to have similar effects on gene expression.  
These results suggest that identification of inverse agonists may be a fruitful approach for 
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G protein coupled receptors (GPCR or GPR) comprise a large superfamily of 
receptors characterized by a seven transmembrane domain structure and an ability to 
activate intracellular transducer G proteins. Over 800 GPCRs in five main families have 
been identified in eukaryotes on the basis of genomic sequence analysis [1]. These 
receptors can be activated by hormones, neurotransmitters, odorants, light, or 
pheromones (Figure 1.1). Orphan GPCRs are a group of receptors for which the 
endogenous agonist is not known or remains unclear or in dispute. The application of 
drug screening, binding assays, and second messenger profiling techniques has decreased 
the numbers of orphan G protein coupled receptors from 150 in 2004 [2] and to as few as 
77 in 2014 [3]. The first receptor to be “de-orphanized” (or “adopted”) was the serotonin 
(5-HT1A) receptor [4]. This process continued with new methods that allowed high 
throughput screening for endogenous activating molecules for the remaining orphan 
receptors [5]. However, in recent years the rate of de-orphanization appears to be slowing 
[6].  
 Muscarinic receptor subtypes (M1-M5) differ in the coupling to cellular effector 
mechanisms. M2 and M4 receptors generally couple most efficiently to inhibition of 
certain isoforms of adenylate cyclase lowering cytosolic cAMP levels as a consequence 
of interactions with Gi transducer proteins, while M1, M3 and M5 couple most 
efficiently to the stimulation of phospholipase C causing a mobilization of intracellular 
calcium as a consequence of interactions with Gq/11 proteins [7-9]. This specificity is not 





Figure 1.1. Basic principle of GPCR-mediated signal transduction. A, Molecular  
representation of a GPCR based on the x-ray crystal structure of rhodopsin. Helices 3 and 
6 are shown in blue and green, respectively. B, Basic pattern of ligand-mediated GPCR 
signal transduction. After ligand agonist binding, the receptor undergoes conformational 
changes, which promotes the coupling with heterotrimeric G proteins (Gαβγ) and 
catalyzes the exchange of GDP by GTP on the α-subunit. This event engages 
conformational and /or dissociational events between the α- and βγ-subunits, and both 
GTP-bound Gα-subunit and the Gβγ-dimer can then modulate the activity of various 
effectors. For example, stimulation or inhibition of adenylyl cyclase (AC)-mediated 
cAMP synthesis by the α-subunit of the Gs or Gi families, respectively; production of 
inositol 1,4,5-triphosphate (IP3) and 1,2-diacylglycerol (DAG) after cleavage of 
phosphatidylinositol 4,5-biphosphate (PIP2) by Gαq stimulation of phopholipase C 
(PLC); activation of Gi and Go also mediated most of the Gβγ-mediated signaling 
processes such as activation of GIRK. Directly from [14]. 
 
 
M2 receptors inhibit adenylate cyclase, they can (in appropriate systems and under 
certain conditions) stimulate adenylate cyclase and phospholipase C[11,12]. M3 
receptors can also stimulate adenylate cyclase at high agonist concentrations.  
This multiplicity of actions reflects multiplicity of signal transduction effector 
isoforms (e.g., 10 isoforms of adenylate cyclase), crosstalk between signaling pathways, 
and cell type specific differences in the expression of signaling proteins. Crosstalk 
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between pathways can take place at different levels: at the receptor level, signaling 
potential is affected by the level of receptor expression [15]; at the transduction level, M2 
receptors can directly activate multiple transducer G proteins (Gαi and Gαs) [11]; at the 
second messenger level, cAMP, inositol trisphosphate,  Ca
2+
, and diacylglycerol can 
activate or inhibit protein and enzymes that in turn regulate both receptors and effector 
molecules.  
 Signaling mediated by second messengers transiently regulates cell processes, 
many of which lead to changes in transmembrane potential and thus electrical excitability 
of the cell [16]. However, long term changes in cell behavior require the integration of 
second messenger activity (proximal signaling) into changes in gene expression (distal 
signaling) (Figure 1.2).  Measurement of these second messengers can sometimes be 
problematic, especially in the case of inhibitory pathway activation (ie. Gαi).  Under these 
conditions it is useful to artificially elevate second messenger (cAMP) levels in order to 
more easily visualize the inhibition of that pathway.  Forskolin (Figure 1.3), a diterpene 
derivative, has been used previously for this purpose [17].  Acting as a potent stimulator  
of adenylate cyclase, this compound increases the frequency and length of time that the 
enzymatic site is formed via the binding of the two catalytic domains [18] (Figure 1.4).   
While these two domains are in contact, the active site can catalyze the formation of 
cAMP via Mg
2+
 assisted ring formation [19] (Figure 1.5). This activity is directly 
opposed by the binding of inhibitory G proteins via a decrease in catalytic domain 
affinity, thus decreasing the stimulatory effect of Forskolin [20].  
 The phenomenon of agonist-independent “constitutive” signaling (Figure 1.6) was 




Figure 1.2. G protein signaling pathways. A schematic diagram showing how, after  
stimulation of the GCPR and dissociation of the G-protein subunits, the major G-protein 
families signal via the different intracellular second messenger pathways to communicate 
with nuclear promoter elements. (a) Gαs-coupled receptors stimulate adenylyl cyclase 
(AC), which synthesises cAMP from ATP. In contrast Gαi-coupled receptors inhibit AC 
and so reduce cAMP formation. (b) The βγ subunits from Gαi and other G proteins are 
able to activate the MAP kinase pathways and PLCβ. (c) GPCRs coupled to the Gαq 
family of G proteins stimulate PLCβ, which cleaves membrane phospholipids to produce 
IP3, which mobilises intracellular calcium, and DAG, which activates PKC. (d) Second 
messenger pathways then activate a range of effector systems to change cell behaviour; in 
many cases this includes the regulation of gene transcription. Dotted line shows a more 
indirect pathway. MAPK, MAP kinase, MEK, MAP kinase kinase; P, phosphate; PIP2, 
phosphatidylinositol-4,5-bisphosphate. Taken directly from [22]. 
 
 
discovery of mutant versions of other native GPCRs that signal in a similar manner [23]. 
Constitutive activity is now known to be present in a large number of GPCRs. As of this 
publication, a PubMed search for “GPCR” and “constitutive” reveals 132 references 






Figure 1.3. Structure of Forskolin.  This molecule interacts directly with both  






Figure 1.4. Activity of Forskolin, Gαi and Gαs in regulating Adenylate Cyclase. The two 
catalytic domains of Adenylate Cyclase normally have very low affinity for each other.  
Formation of cAMP can only occur when these two domains bind together, forming the 
active site.  Forskolin, a diterpene binds to both C1 & C2 domains via hydrogen bonding 
and hydrophobic interactions increasing their affinity.  Gαs and Gαi work in antagonistic 











Figure 1.5. Formation of cAMP is dependent on both catalytic domains.  Coordination of  
metal ions (Mg
2+
) allow for interactions between the two catalytic domains (C1 in green, 
C2 in red).  Conformational changes of individual residues during catalysis are marked. 





lengthening the sixth transmembrane domain [24]. Structural analyses of some receptors 
suggest that this mutation eliminates interactions between hydrophobic amino acids on 
the third and sixth transmembrane, leading to the formation of a water filled pore [25] 
[26]. This led to a “unifying” theory on the biochemical mechanisms that regulate GPCR 
activation, including the changes that may lead to constitutive signaling [27]. 
The use of constitutive signaling poses certain challenges.  There is the risk that 
endogenous ligands or activating conditions may be present in the testing media, thereby 
confounding data interpretation, as was the case for the ADORA2 receptor [28].  
Receptors can also respond differently under different conditions, either due to 




Figure 1.6. Agonist vs. Constitutive activation of GPCR signaling. G protein coupled 
receptors (GPCR, or GPR) are in a constant equilibrium between the inactive (R), and 
active (R*) forms of the protein.  The ratio of the two (R*/R) can be expressed as an 
equilibrium constant. “Agonists” are ligands that act to destabilize the inactive form of 
the receptor shifting the equilibrium to the active conformation, thus recruiting and 
activating intracellular G proteins, which in turn activates downstream second messenger 
synthesis/release. Constitutive activity occurs when the Keq of the native receptor is large 
enough that the GPCR can activate signal cascades in the absence of a ligand.  Inverse 
Agonists are molecules that bind to the agonist active site but act as stabilizing agents for 
the inactive form, thus shifting equilibrium away from the active state and preventing 





hetero-dimerization with other native receptors [30]. Nevertheless, constitutive signaling 
has been useful in the discovery of native ligands [31], and is a required for the 




Constitutive signaling as a tool in orphan receptor characterization was reviewed 
in 2006 [32]. The history of inverse-agonists (i.e., compounds that inhibit constitutive 
activity) as a therapeutic approach has also been reviewed [33].  While the use of 
constitutive signaling for drug discovery (notably, for inverse-agonists) has been 
discussed [5], the use of constitutive signaling to de-orphanize or to understand potential 
signaling pathways in GPCRs has not been widely exploited.  Accordingly, this work was 
developed to experimentally establish that distal signaling via a Luciferase linked 
reporter vector could be used to measure and characterize cAMP dependent constitutive 




1.2.1. Section 2: Establishing the Assay.  Experiments performed in this section 
compared cross talk patterns in receptor signaling at distal levels of the signaling cascade.  
Specifically, gene activation by muscarinic receptors (M1 – M5; GenBank AF498915-9) 
possessing a wild type (WT) or constitutively active (CA) phenotype were examined.  
Comparing signaling pathways of known receptors (M1-M5) with known responses vs. 
the characterization of constitutively active mutant (CAM) receptors of the same family 
established the validity of the assay and supported its use in the characterization of 




1.2.2. Section 3: Constitutive Signaling Among Orphan Receptors.  The 
prevalence of constitutive activity among Class-A orphan GPCRs has 
not been comprehensively examined. Experiments performed in this section examined 40 
class-A orphan G protein coupled receptors to determine the prevalence of cAMP 
dependent constitutive signaling (i.e., signaling that is generally mediated by Gαi and Gαs 
transducer proteins), using receptor activation or inhibition of gene expression under 
control of the cAMP-dependent response element (CRE) as the indicator of pathway 
activation.   
1.2.3. Section 4: Summary, Discussion, and Impacts.  Considering the nature of   
the subject under evaluation, an initial “Review of Literature” option would not be 
appropriate.  This section provides an individual review of the literature on each orphan 
GPCR examined within this work and discusses the results of experiments performed. 
Indications of agreement/disagreement with established receptor behavior is noted, as 
well as the contribution of this work towards that body of knowledge. 
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2. ESTABLISHING THE ASSAY 
2.1. METHODS 
2.1.1. Cell Culture. CHO-K1 wild-type Chinese hamster ovary (CHO)  cells 
were obtained from the American Type Culture Collection (ATCC). CHO cells stably 
transfected with the coding sequences for M2 or M3 muscarinic receptor (CHO-M2 and 
CHO-M3; GenBank AF498916; GenBank AF498917, respectively) were obtained from 
the cDNA Resource Center (www.cdna.org). Cells were maintained at 37
o
C with 5% 
CO2.  Culture media consisted of 90% HyClone DMEM (without phenol red or additional 
L-glutamine) supplemented with 10% HyClone FetalClone II (bovine serum product).  
Plates were allowed to reach 80% confluency before being split for growth or use in 
subsequent experiments. 
2.1.2. CRE Regulated Gene Expression. A luciferase coupled reporter vector  
(Promega) was used to monitor CRE regulated gene expression in CHO cells. CHO cells 
in (200,000 in 100 µl media) were plated onto 96-well plates and incubated until they 
reached 80% confluency.  Cells were mixed with firefly luciferase reporter vector 
(Promega) at a final concentration of 250 ng per well and Lipofectamine 2000 Reagent 
(Invitrogen), following manufacturer’s suggested protocols. In some experiments, CHO 
cells were co-transfected with clones for a specific subtype of muscarinic receptor (M1 – 
M5) possessing either a wild type (WT) or constitutively active (CA) phenotype in a 
pcDNA3.1+ vector (Invitrogen) obtained from the cDNA Resource Center 
(www.cdna.org), and incubated for 24 hours. Transfection with an empty pcDNA3.1+ 
vector served as a control. In other experiments, the reporter gene vector was transfected 
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into CHO cells stably expressing a muscarinic receptor cDNA clone (obtained from the 
cDNA Resource Center; www.cdna.org). 
 Transfection media was removed and replaced with complete media. The plate 
was then incubated for an additional 6 hours. Immediately prior to visualization, each 
well was rinsed with PBS and replaced with 50ul of DMEM (-phenol red) without serum. 
Controls and treatments intended to test Gαi signaling (i.e., inhibition of adenylate 
cyclase) were exposed to 3 µM forskolin (Sigma Aldrich) to activate the catalytic subunit 
of the cyclase. Imaging was performed using a FLUOstar Omega (BMG Labtech) 96-
well plate reader.  Auto-injection of 25ul of Bright-Glo Luciferase Reagent (Promega) 
was followed by 2 minutes of rotary incubation.  Relative Light Units (RLUs) were 
measured in each well for 1 minute.  Each plate was repeated in triplicate and contained 
12 treatment groups with 4 replicates in each group, separated by a row of unused wells 
to minimize light pollution. Control treatments (3 µM forskolin stimulated cells with 
CRE-Luciferase and empty pcDNA3.1+) were used to standardize RLU values between 
plates.   
2.1.3. Data Analysis. Experiments were performed 3-8 times in triplicate or 
quadruplicate. Data is expressed as the mean and standard deviation from the 
independent experiments. Measurements from two populations (e.g., wild type vs. 
constitutively active receptors) were compared using Student’s t-test. Values from 
experiments with multiple independent variables (e.g., concentration curves) were 
compared by ANOVA and Tukey’s test using GraphPad Prism software. Significant 





2.2.1. Activation of Gene Expression Under Control of the cAMP Response 
Element (CRE) in CHO-M2 Cells.  Dose-response curves for forskolin induced gene 
expression mediated by CRE were determined.  Direct enzymatic activation by forskolin 
was not affected by receptor expression (i.e., was identical in wild type, M2-expressing 
and M3-expressing CHO cells).  The concentration relationship for forskolin activation 
depended on the length of exposure to forskolin (Fig 2.1). When exposed to forskolin for 
15 minutes followed by removal by washing, gene expression 6 hours later was increased 
by forskolin only at concentrations above 10 µM (Figure 2.1.A). When the forskolin was 
not removed from the incubation medium, the threshold was 30 fold lower (≈ 0.3 µM).  
These effects of forskolin were independent of receptor expression. Thus, emphasizing 
that gene expression assays provide a valid and reliable means of characterizing distal 
GPCR signaling.  
 CHO-M2 cells potentiate adenylate cyclase at 100uM of Carbamylcholine, showing 
increased expression of luciferase under control of the CRE. The increase in reporter 
gene expression in response to 100 µM carbamylcholine was significant within 2.5 hours 
and peaked after 8 hours (Figure 2.1.B). In subsequent expressions, a 6 hour incubation 
period was routinely used. 
2.2.2. CRE-Mediated Gene Expression Stimulated by each WT and CA 
Muscarinic Receptor Subtype; Distal Receptor Signaling is Potentiated by 
Constitutive Activity.  Luciferase reporter assays were used to compare second  
messenger signaling with signaling patterns integrated at the gene expression level in 





Figure 2.1. Carbamylcholine and forskolin activation of CRE-mediated expression of a 
reporter gene in CHO-WT cells. RLU, relative luminescent units.  
Figure 2.1.A. CHO wt cells were incubated with the indicated concentrations of 
forskolin. In the “Acute” condition, the cells were exposed to forskolin for 15 min and 
then the forskolin was removed by replacing the media; in the “Chronic” condition, 
forskolin was present throughout the 6 hour incubation.  
Figure 2.1.B. CHO-M2 cells were incubated with 100 µM carbamylcholine for the 
indicated times before measuring luminescence catalyzed by reporter gene generated 





 Constitutively active muscarinic receptors were created by inserting two amino acids 
into the sixth transmembrane domain.  This alteration conveys a constitutively active 
phenotype in many G protein coupled receptors [24], possibly by disrupting a 





domains[25-27].  Constitutive activity was associated with a higher level of basal CRE-
mediated gene expression with all 5 receptor subtypes, although M3 receptors showed the 
greatest fractional response (≈ 700%) and M2 and M4 showed the lowest fractional 
responses (≈ 100%) (Figure 2.2).  Carbamylcholine increased expression mediated by all 
CA receptors subtypes except M4. The greatest increases (and lowest basal activities) 






Figure 2.2. Stimulation of CRE-mediated gene expression by activation of the five 
muscarinic receptor subtypes with either a wild type (WT) or constitutively active (CA) 
phenotype. CHO cells were transiently transfected with genes for each of the muscarinic  
receptors subtypes (M1 – M5, WT or CA). Activity was measured 24 h later in the 
absence or presence of 100 µM carbamylcholine and is expressed as relative 
luminescence units normalized to activity measured in the presence of 3 µM forskolin. 
Mean ± SD; N = 4. Carbamylcholine increased expression mediated by all WT receptors 
subtypes except M4; receptors with constitutive activity had greater activity than wild 
type receptors of the same subtype; carbamylcholine further increased the activity of all 
subtypes with a CA phenotype, except M4 (all comparisons by Student’s t-test; p < 0.05). 
 
 
2.2.3. Agonist Concentration Dependence of CRE-Mediated Gene Expression 
Stimulated by WT and CA M2 and M3 Muscarinic Receptors. CRE mediated gene 
expression assays were used to further characterize the signal transduction potential of 
M2 and M3 (WT and CA) receptors, since these two receptors exhibit the strongest 
activation in the classes of receptor subtypes (i.e., Gi- and Gq/11-coupled receptors).  
Basal levels of CRE-mediated gene expression were more than doubled in the CHO cells 
expressing M2 or M3 receptors with a CA phenotype (Figure 2.2). CRE-mediated 
activity was further increased by carbamylcholine in cells expressing either the M2 or M3 








Figure 2.3.  Influence of constitutively active (CA) phenotype on stimulation of CRE-
mediated expression in cells transiently expressing M2 (left) and M3 (right) receptors. 
Activity is expressed as relative luminescent units normalized to background 
luminescence (sham reporter gene transfection) and the response obtained at the highest 
agonist concentration. Basal levels of CRE-mediated gene expression were 123 ± 21% 
and 115 ± 26% greater in the cells expressing M2 and M3 receptors with a CA 
phenotype, respectively (p < 0.05; N = 3; Student’s t-test). Mean ± SD from 4 
determinations from a typical experiment repeated 5 (M2) or 3 (M3) times with 





CA M2 receptors, but not CA M3 receptors responded to carbamylcholine with a lower 
threshold than the corresponding WT receptors. 
2.2.4. Concentration-Dependent Inhibition and Activation of CRE Mediated 
Gene Expression by M2 Receptors. It is generally recognized that M2 receptors  
preferentially activate Gi proteins thereby attenuating adenylate cyclase activity[7-9]. It 
is readily apparent form the experiments depicted in Figures 2.1, 2.2, and 2.3 that M2 
receptor subtypes can also stimulate adenylate cyclase activity and CRE-mediated gene 
expression at high concentration of agonists.  As shown in Figure 2.4 the nature of these 




Figure 2.4. Carbamylcholine inhibition/stimulation of CRE-mediated gene expression of 
luciferase in CHO-M2 cells. Activity is expressed as relative luminescent units  
normalized to the response produced by a maximally effective concentration of 
carbamylcholine. Measurements were made in the absence (Control) and presence of 0.6 
µM forskolin, as indicated. Mean ± SD from 4 determinations from a typical experiment 
repeated 4 times with essentially similar results. Carbamylcholine attenuated gene 
expression in the presence of forskolin at 1 and 10 nM (ANOVA; p < 0.05), but the EC50 
values for carbamylcholine activation of response in the two conditions were not 
different. Inhibition of forskolin stimulation under low concentrations of carbamylcholine 





expression under control of CRE in CHO-M2 cells was determined. Carbamylcholine 
activated gene expression following a 6 hour incubation with an EC50 of ≈ 30 µM. While 
inclusion of 0.6 µM forskolin in the incubation medium increased the response at higher 
agonist concentrations by ≈ 40%, an inhibition of response was revealed at very low 
concentrations of carbamylcholine (1-10 nM), presumably reflecting Gmediated 
inhibition of adenylate cyclase.  This result is consistent with previous observations in 
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literature cited above and further demonstrates the close correlation between M2 receptor 
alterations of CRE mediated gene expression and cAMP production. 
 
2.3. DISCUSSION 
 Activation of the G protein-coupled muscarinic receptors leads to relatively rapid 
changes in transmembrane potential through modulation of ion channels and transporters, 
either directly or through second messenger-mediated events [16]. Activation of the same 
receptors also leads to changes in gene expression mediated by second messenger 
activation of kinase cascades whose targets include transcription factors. The purpose of 
these experiments was to increase understanding of crosstalk signaling in muscarinic 
systems and to establish the efficacy of this experimental assay in characterization of 
constitutively signaling receptors. Specifically, this work compared crosstalk in distal 
signaling events (second messenger production causing altered gene expression), to 
evaluate the persistence of cross talk signaling in receptors with a constitutively active 
phenotype, and to evaluate the potential for these effects in all 5 receptor subtypes which 
represent multiple signaling profiles. 
2.3.1. Canonical Muscarinic Signaling in CHO Cells.  CHO cells are a widely  
used model system in biomedical research, including cellular signaling pathways, due to 
their robust growth and amenability to transfection and expression of recombinant 
proteins. In wild-type CHO cells, acetylcholinesterase activity, muscarinic receptor 
binding, or muscarinic signaling is not detected in either calcium mobilization or 
alteration of cAMP synthesis in response to the muscarinic agonist carbamylcholine. 
However, CHO cells express components of both the phospholipase C (influencing AP-
1 and NFAT) [34,35] and adenylate cyclase (CRE) [36] signaling pathways, and CHO 
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cells transfected with transgenes for the different muscarinic receptor subtypes respond to 
muscarinic agonists in pharmacologically and physiologically appropriate manners: 
Activation of human M1, M3 or M5 receptors expressed in CHO cells leads to the 
production of IP3, release of calcium from the ER, activation of store-operated calcium 
entry, and modulation of the expression of genes under their control. Activation of human 
M2 and M4 receptors expressed in CHO cells leads to the inhibition of forskolin-
stimulated cAMP formation and alteration of the expression of genes under the control of 
the cAMP response element (CRE) [36].  
2.3.2. Crosstalk in Muscarinic Signaling.  A myriad of studies have shown that  
M2 and M4 receptors couple efficiently to Gi transducer proteins to inhibit adenylate 
cyclase, while M1, M3 and M5 couple more efficiently to the stimulation of 
phospholipase C as a consequence of interactions with Gq/11 proteins[7-10]. Crosstalk 
at this level of the signal transduction cascade encompasses the ability of specific 
receptors to interact with different transducer G proteins, thereby activating different 
pathways. The factors that affect receptor/G protein coupling status are incompletely 
understood, but in experimental systems include identity and concentration of the agonist 
as well as receptor/G protein stoichiometry [11,12,15].  
 M2 receptor activation inhibits forskolin-stimulated cAMP formation at relatively 
low (EC50 ≈ 0.1 µM) but stimulated adenylate cyclase activity at high concentrations (> 
100 µM). This is consistent with earlier studies [11]. Clearly, M2 receptors have an 
intrinsic ability signal through either pathway. As a consequence of this crosstalk 
signaling, M2 activation increases gene expression under the control of the CRE, even at 
concentrations at which an increase in cAMP production is not apparent. In the presence 
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of forskolin, a decrease in CRE-mediated gene expression is evident [11], paralleling the 
inhibition of cAMP production. Thus, the major features of M2 – Gi crosstalk seen at 
the level of adenylate cyclase regulation are also evident at the level of regulation of gene 
expression.  
 Many class A GPCRs can be endowed with constitutive activity by slightly 
lengthening the sixth transmembrane domain [24]. Structural analyses of muscarinic 
receptors suggest that this mutation eliminates interactions between hydrophobic amino 




 transmembrane, leading to the formation of a water filled pore 
[25-27].   M2 receptors with constitutive activity thus conferred mediate enhanced 
crosstalk signaling through the Gs pathways.  
 A CA-inducing mutation increases CRE-mediated gene expression activity of all 
muscarinic receptor subtypes. This is of course expected with M1, M3 and M5 receptors, 
but was equally evident with M2 and M4 receptors. Moreover, carbamylcholine further 
activated CRE-mediated gene expression of all muscarinic receptors subtypes except M4. 
This suggests that the degree of receptor activation by CA-inducing mutation is less that 
that produced by a receptor agonist. These measurements were preformed following 
transient expression of the CA receptor variants. Attempts to produce a stably transfected 
cell line constitutively expressing increased cAMP levels were met with no success.  
 
2.4. CONCLUSIONS 
 Muscarinic receptors activate both preferred and secondary signaling pathways 
through activation of different G proteins. Both M2 (preferred signaling through Gi) and 
M3 (preferred signaling through Gq/11) activated adenylate cyclase (Gs signal) at high 
agonist concentrations, and these increases in cAMP resulted in upregulation of distal 
  
20 
reporter gene expression under control of the cAMP-dependent response element. These 
results demonstrate that gene expression assays are a viable and reliable means to 
characterize receptor-signaling pathways, and reveal similar promiscuity of receptors 
with respect to signaling pathway.  
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3. CONSTITUTIVE SIGNALING AMONG ORPHAN RECEPTORS 
3.1. METHODS 
Histamine, Muscarinic and Orphan GPCR receptor genes, cloned into 
pcDNA3.1+ (Life Technologies) were acquired from the MS&T cDNA Resource Center 
(www.cdna.org).  These constructs were transiently co-transfected with Luciferase 
coupled reporter vectors to monitor CRE dependent gene expression. Each experimental 
treatment involved 4 wells seeded with 40,000 CHO-K1 cells in 96-well plates and 
incubated for 24 hours. Experiments were repeated 4 to 8 times. An “empty” plasmid 
(pcDNA3.1+) was used as a transfection negative control. Forskolin (3µM) mediated 
stimulation of adenylate-cyclase served as a positive control for the assay and 
additionally was used to normalize responses across experiments.  Forskolin was 
administered 6 hours prior to measurements concurrently with sham dosing (media) 
where appropriate. Receptor activity was reflected by induction of luciferase expression 
under the control of the cAMP response element (CRE).  
3.1.1. Cell Culture. CHO-K1 wild-type Chinese hamster ovary cells were 
obtained from the American Type Culture Collection (ATCC) and maintained at 37
o
C 
with 5% CO2 as  previously described [37].  Culture media consisted of 90% HyClone 
DMEM (without phenol red or additional L-glutamine) supplemented with 10% HyClone 
FetalClone II (bovine serum product).  Plates were allowed to reach 80% confluency 




3.1.2. Transfection. Approximately 40,000 CHO-K1 cells in 100 µl of media 
were plated onto a 96-well plate and allowed to attach overnight and incubated until they 
had reached 80% confluency.  Firefly Luciferase reporter vector (pGL4.29, Promega) 
was mixed with plasmid DNA containing orphan receptor GPCR coding sequences 
(Missouri S&T cDNA Resource Center, www.cdna.org) or an empty pcDNA3.1+ vector 
(Life Technologies) at a final concentration of 250 ng each per well. Transfection was 
carried out following manufacturer’s suggestions (Lipofectamine 2000 Reagent, Life 
Technologies), followed by an 18 h incubation before use.  
3.1.3. Luciferase Assay.  Transfection medium was removed and replaced with  
complete medium. Controls and treatments intended to evaluate inhibition of the cAMP 
pathway (i.e., putative Gα-i signaling) were treated with 3.0 µM Forskolin (Sigma 
Aldrich).  The plate was then incubated for an additional 6 hours. Immediately prior to 
visualization, the medium within each well was replaced with 25 µl of DMEM (-phenol 
red) without serum.  
Imaging was performed using a FLUOstar Omega (BMG Labtech) 96-well plate 
reader.  Auto-injection of 25ul of Bright-Glo Luciferase Reagent (Promega) was followed 
by 2 minutes of rotary incubation.  Relative Light Units (RLUs) were obtained for each 
well in series over 1 minute.  Each 96-well plate consisted of 12 treatment groups with 4 
replicates in each group. Each treatment group was separated by a row of unused wells to 




3.1.4. Data Analysis. Statistical analysis was performed in MiniTab, version 17, 
using a randomized complete block design.  This variant of an ANOVA analysis takes 
differences between experiments (plates/blocks) into account and also allows for 
examination of treatment-block interaction.  This statistical analysis allows for a strong 
isolation of treatment effect within the experiments. 
Each experimental group (n=4) was divided by the average of the positive control 
treatments (3 µM Forskolin stimulated cells with CRE-Luciferase and empty 
pcDNA3.1+,  n=4) to normalize results between plates.  Each experimental treatment was 
then divided by its control (+/- 3 µM Forskolin) to determine the fractional stimulation or 
inhibition. Data was graphed as the average percent change over control between 4 to 8 
plates with the over-all treatment p-value for each comparison indicated via either a 
single star for a threshold of 0.05, or a double star indicating a threshold of 0.01.  
Treatment effects that did not meet either of these thresholds were displayed individually 
and in red.   
 
3.2. RESULTS & DISCUSSION 
Orphan receptors were judged to be constitutively active if they significantly 
affected cAMP dependent signaling (p < 0.05, according to a randomized complete block 
ANOVA , 4 - 8 experiments) and additionally fulfilled at least one of the following 
criteria: 1) 200% elevation over baseline reporter gene expression, 2) 40% inhibition of 
baseline expression, or 3) 40% inhibition of expression stimulated by 3 µM forskolin.  
These criteria were chosen to reflect thresholds large enough to minimize false-positives 
due to receptor over-expression.  Among the 40 orphan receptors evaluated, 75% (30) 
met criteria for constitutive activity.   
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GPCR’s are characterized by their interaction with specific transducer G proteins. 
Gαs and Gαi play opposing roles in modulating cAMP levels in response to external 
stimuli by mediating the activation and inhibition of adenylate cyclase respectively.  
While this work did not directly measure association with either Gαs or Gα, changes in 
gene expression under control of the cAMP-dependent response element (CRE) were 
considered to indicate the involvement of pathways mediated by these transducers. Five 
patterns of signaling were noted. 
 
3.2.1. Group A: Constitutive Inhibition of Baseline and Forskolin Stimulated 
CRE-Dependent Expression. As shown in Figure 3.1, the largest group of receptors  
(17 of 40) exhibited significant constitutive inhibition of CRE-mediated gene expression 
under both baseline and forskolin-stimulated conditions.  This group is comprised of 
GPR15, GPR17 variant 3, GPR18, GPR20, GPR25, GPR27, GPR31, GPR32, GPR45, 
GPR55, GPR57 variant 1, GPR68, GPR83, GPR84, GPR132, GPR150, and GPR176.  In 
all cases, the statistical significance level was less than 0.01.   
This behavior is similar to results obtained with the histamine receptor 4 (HRH4), 
a receptor with known constitutive signaling through the Gαi pathway [38] using this 
experimental design. While all 17 of these receptors inhibited gene expression by over 






Figure 3.1.  Group A: Constitutive inhibition of baseline (B) and forskolin stimulated 
CRE-dependent expression (F). The percent change of cAMP-dependent signaling in  
CHO-K1 cells transfected with CRE-Luciferase reporter vector and an orphan G protein 
coupled receptors is shown.  Activity was measured as relative light units (RLU) and 
normalized between experiments by dividing by the average of the 3 µM Forskolin 
stimulated control within each plate.  This value was then divided by the control for each 
condition to obtain the fractional change, with a value of zero indicating no change from 
control levels. Vertical dotted lines represent the minimum signaling threshold to be 
scored as constitutively active within this study.  Changes in basal cAMP dependent 
expression are indicated by the light blue bars labeled “B”.  Changes in expression in the 
presence of 3 µM Forskolin (6 hour exposure) is indicated by the dark blue bars labeled 
“F”.  All receptors presented in this figure showed a significant treatment effect (** = p < 
.01) and met the criteria adopted in this work to define constitutive activity.  
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3.2.2. Group B: Constitutive Stimulation of Baseline and Inhibition of 
Forskolin Stimulated Expression. As shown in Figure 3.2, this group is comprised of 
 receptors that are closely related in terms of amino acid homology: GPR6 and GPR12 
[39]. A third member of this family (GPR3) produced extremely variable effects on 
forskolin stimulated expression and its inhibition within these experiments was not 
statistically significant (p = 0.072).  Accordingly, it was included in group D. 
Receptors in this group exhibited constitutive stimulation of CRE-mediated gene 
expression under baseline conditions while inhibiting CRE-mediated gene expression 
stimulated by 3 µM forskolin. Thus, these GPCRs can constitutively stimulate at least 
one aspect of baseline cAMP-mediated signaling (i.e., CRE mediated gene expression) 
while inhibiting high levels of cAMP-mediated signaling induced by an exogenous agent 
(forskolin). It is possible that these receptors act to maintain an elevated but controlled 
homeostatic level of cAMP by this pathway, a function known to be present in 
maintenance of meiotic arrest in oocyte development [40]. 
3.2.3. Group C: No Effect on Baseline Expression but Inhibit Forskolin 
Stimulated Expression. As shown in Figure 3.3, this group is comprised of GPR4, 
GPR26, GPR61, GPR62, GPR78, GPR101, and GPR119. These receptors did not alter 
baseline signaling enough to meet criteria for constitutive activity, although they all 
inhibited CRE mediated gene expression stimulated by 3 µM forskolin by at least 40%.  
In this way, they are similar to results obtained with a constitutively active mutant 
version of the M2 acetylcholine receptor, which is capable of signaling through both the 
Gαs and Gαi pathways [12,13].  
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While baseline stimulation did not meet criteria for constitutive activity as defined 
in this study, many of the receptors in this group produced a very significant “block” and 
“treatment by block” effect (p < 0.01). Further measurements may reveal constitutive 






Figure 3.2. Group B: Constitutive stimulation of baseline (B) and constitutive inhibition 
of forskolin stimulated CRE-dependent expression (F). The percent change in cAMP  
dependent signaling in CHO-K1 cells transfected with CRE-Luciferase reporter vector 
and various orphan G protein coupled receptors is shown.  Vertical dotted lines represent 
the minimum signaling threshold to be scored as constitutively active within this study.  
Activity was measured, normalized and graphed as described in the legend to Figure 3.1. 
Changes in basal cAMP dependent expression are indicated by the light blue bars labeled 
“B”.  Changes in expression in the presence of 3 µM Forskolin (6 hour exposure) is 
indicated by the dark blue bars labeled “F”.  Members of this group showed a significant 
treatment effect (** = p < .01) and met the criteria adopted in this study to define 









Figure 3.3. Group C: No effect on baseline (B) and constitutive inhibition of forskolin 
stimulated expression (F). The percent change in cAMP dependent signaling in CHO-K1  
cells transfected with CRE-Luciferase reporter vector and various orphan G protein 
coupled receptors is shown.  Activity was measured, normalized and graphed as 
described in the legend to Figure 3.1. Vertical dotted lines represent the minimum 
signaling threshold to be scored as constitutively active within this study.  Changes in 
basal cAMP dependent expression are indicated by the light blue bars labeled “B”.  
Changes in expression in the presence of 3 µM Forskolin (6 hour exposure) is indicated 
by the dark blue bars labeled “F”.  Members of this group showed significant treatment 
effect (** = p < .01) but did not meet criteria for constitutive activation of 200% 
stimulation over baseline expression levels (B).  All members displayed constitutive 









3.2.4. Group D: Stimulation of Baseline Expression but No Inhibition of 
Forskolin Stimulated Expression. As shown in Figure 3.4, this group is comprised of  
GPR3 and GPR65 along with the closely related GPR21 and GPR52 [39]. These 
receptors exhibited constitutive stimulation of baseline cAMP dependent signaling 
without any constitutive inhibition of the signaling stimulated by 3 µM forskolin.  This is 
similar to CRE-mediated responses noted in the constitutive mutant of the M3 human 
muscarinic acetylcholine receptor that signals through Gαq and Gαs activation without 






Figure 3.4. Group D: Stimulation of baseline (B) but no change of forskolin stimulated 
expression (F). The percent change in cAMP dependent signaling in CHO-K1 cells  
transfected with CRE-Luciferase reporter vector and various orphan G protein coupled 
receptors is shown.  Activity was measured, normalized and graphed as described in the 
legend to Figure 3.1. Vertical dotted lines represent the minimum signaling threshold to 
be scored as constitutively active within this study.  Changes in basal cAMP dependent 
expression are indicated by the light blue bars labeled “B”.  Changes in expression in the 
presence of 3 µM Forskolin (6 hour exposure) is indicated by the dark blue bars labeled 
“F”.  Members of this group showed a significant treatment effect (* = p < .05, ** = p < 
.01) and an increase of CRE-mediated gene expression of more than 200% under baseline 
conditions (B), but did not affect gene expression stimulated by 3 µM forskolin (F). 
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3.2.5. Group E: Non-Responders with No Constitutive Activity. As shown in 
Figure 3.5, this group is comprised of the remaining 10 orphan receptors: GPR1, GPR19, 
GPR22, GPR34, GPR35, GPR39, GPR63 variant 2, GPR82, GPR85, and GPR87.These 
receptors lacked constitutive activity insofar as they failed to either have a significant 
treatment effect or meet at least one of the three criteria for constitutive activity (i.e., 
200% baseline stimulation, 40% inhibition of baseline, or 40% inhibition of forskolin-
stimulated activity).  Thus, not all orphan receptors exhibit constitutive signaling by 
criteria established in this work. Accordingly, the constitutive activity noted is unlikely to 
be due to an artifact arising solely from overexpression of receptor proteins in this 
system.  
Several of the receptors in this group displayed large fluctuations in response 
from plate to plate, resulting in either loss of a significant treatment affect, or very 
significant “block” and/or “treatment by block” effect (p < .01).  The reasons for this 
variability are not understood but suggest the presence of undefined variables in these 





Figure 3.5.  Group E: No constitutive activity. The percent change in cAMP dependent  
signaling in CHO-K1 cells transfected with CRE-Luciferase reporter vector and various 
orphan G protein coupled receptors.  Activity was measured, normalized and graphed as  
described in the legend to Figure 1. Vertical dotted lines represent the minimum signaling 
threshold to be scored as constitutively active within this study.  Changes in basal cAMP 
dependent expression are indicated by the light blue bars labeled “B”.  Changes in 
expression in the presence of 3 µM Forskolin (6 hour exposure) is indicated by the dark 
blue bars labeled “F”.  Receptors in this group failed to meet either study criteria of a 
significant treatment effect (p value listed in red, * = .05, ** = .01) and/or threshold for 









The purpose of these experiments was to identify the prevalence of constitutive 
activity in the cAMP-dependent signaling pathway within 40 Class-A orphan GPCRs 
using a luciferase-linked gene expression system. The activities examined were 1) 
stimulation of baseline signaling, 2) inhibition of baseline signaling, and 3) inhibition of 
forskolin-stimulated signaling. While 10 of the 40 receptors examined did not display 
constitutive activity, cAMP-dependent constitutive activity was observed in 75% of the 
orphan class-A receptors transiently expressed in CHO-K1 cells. Five groups of receptors 
were defined reflecting different effects on baseline and forskolin-stimulated expression. 
Constitutive inhibition of cAMP-dependent signaling was much more common than 
stimulation (26 vs. 6 receptors), possibly reflecting cytotoxicity associated with high 
levels of cAMP activity.   
Receptors that are closely related on the basis of amino acid homology displayed 
similar response patterns.  For instance, the closely related GPR3, GPR6, and GPR12 all 
stimulated baseline cAMP-dependent signaling while GPR6 and GPR12 both inhibited 
forskolin activated signaling.  Similarly, receptors in a second closely related group, 
GPR21 and GPR52, both stimulated cAMP-dependent signaling without inhibiting 
activity in the presence of forskolin. These results indicate that constitutive signaling is 
an important physiological property of most of the remaining orphan class-A GPCRs and 
may be a reason that many of their native ligands remain elusive. This suggests that a 
search for inverse agonists may be the most effective approach to understanding their 




4. SUMMARY, DISCUSSION, AND IMPACTS 
Examination of CRE-dependent gene expression as a measure of constitutive 
activity in 40 different orphan class-A G protein coupled receptors is so broad a subject 
that a review of pertinent background would be of limited use without the inclusion of the 
results found within this work. Table 4.1 summarizes discussion found below, with 
empty cells indicating no relevant data to report.  Each subsection following reviews the 
literature as pertaining to each individual Orphan GPCR in question, including discussion 
of impacts of results found here-in. 
 
 
Table 4.1. Summary of results and impacts. 
GPR Agree with literature? CA? Impacts 
1  Yes No   
3 Yes Yes   
4 Gαs, but not CA Yes First to claim CA Gαi  
6 Yes Yes First to claim CA Gαi 
12 Yes Yes First to claim CA Gαi 
15 Yes Yes First to claim CA Gαi 
17v3 Yes Yes   
18 Yes Yes   
19 Yes Yes (Gαq)   
20 Yes Yes   
21   Yes (Gαq) First to claim CA Gαs  
22 Yes  (Removed Outlier) Yes   
25   Yes First to claim any CA 
26 Gαs, but not CA Yes First to claim CA Gαi 
27   Yes (Gαq) First to claim CA Gαi 
31   Yes First to claim CA at all 
32   Yes First to claim CA at all 




Table 4.1. Summary of results and impacts cont… 
GPR Agree with literature? CA? Impacts 
35 Yes     
39 Yes  (Removed Outlier) Yes (Gα12) First to claim CA Gαi 
45   Yes First to claim CA Gαi 
52 Yes Yes First to claim CA Gαs  
55   Yes First to claim CA Gαi 
57v1   Yes First to claim CA Gαi 
61 Gαs, but not CA Yes First to claim CA Gαi 
62   Yes First to claim CA Gαi 
63v2 Yes     
65 Yes Yes   
68 No Yes First to claim CA Gαi 
78 No Gαs CA Yes First to claim CA Gαi 
82 Yes   More investigation is needed 
83 No Yes (Gαs) No Gαs; First to claim CA Gαi 
84 Yes Yes   
85     More investigation is needed 
87 Yes     
101 Gαs, but not CA Yes First to claim CA Gαi 
119 No Yes (Gαs) No Gαs; First to claim CA Gαi 
132 No Gαi, or CA Yes First to claim CA Gαi 
150   Yes First to claim CA Gαi 




A homolog of GPR1 in plants has been found to play a role in the formation and 
maintenance of mycorrhiza interactions [41] via increase in cAMP.  Plants with this gene 
knocked out had very limited ability to interact with its fungal counterparts.  These 
limitations were removed via the exogenous stimulation of cAMP. Further studies 
continued to implicate this orphan as involved in the cAMP dependent signaling 
pathways expressed under nutrient (nitrogen) starvation [42] and suggest that it may act a 
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glucose/sucrose sensor in yeast [43] [44].  Investigation of this orphan in animals did not 
reveal a specific pathway but did show an up-regulation in human-smooth muscle in 
response to LDL cholesterol exposure [45]. 
While orphan G protein coupled receptor 1 (GPR1) has been researched by 
multiple groups previously, no mention of specific constitutive activity was found.  This 
is supported by this work, which did not reveal any significant impact on cAMP 
dependent signaling and scored this receptor in Group E: Non-responders.  
 
4.2. GPR3 
GPR3 is the first member of the “3-6-12 family”, a closely related group of 
receptors along with its two “siblings”: GPR6 and GPR12 [39].  This orphan has also 
shown the ability to elevate cAMP levels in multiple studies, although some go so far as 
to assume it is due to simple over-expression of the receptor [46].  It retains a high degree 
of homology between species and has been shown to act to constitutively increase cAMP 
levels in HEK293 cells [47] via transfection.  Evidence that it may be constitutively 
signaling beyond the phenomenon of overexpression is found in its ability to maintain 
high levels of cAMP in Xenopus laevis oocyte development, a condition critical to their 
meiotic arrest [40]. 
 The search for endogenous ligands for this receptor has led to the proposal that it 
and its siblings are activated by short chain free fatty acids (FFA) [48] and the proposal 
of an inverse-agonist with activity specific to GPR3 without affecting GPR6 and GPR12 
[49]. 
 The results of this study agree with previous findings of constitutive elevation of 
cAMP as indicated by a 428% increase in basal cAMP dependent expression of the 
  
36 
luciferase reporter vector.  The response of this orphan under the influence of artificial 
stimulation via 3 µM Forskolin are less clear.  While a majority of plates surveyed did 
show inhibition of the forskolin stimulation well above the 40% minimum, the range was 
too large to maintain statistical significance.  Previous evidence of this inhibitory 
behavior has not been shown for this orphan and could constitute a novel finding with 
further investigation.  
 
4.3. GPR4 
Originally isolated in 1995 [50], GPR4 was not highly studied until a few years 
later. It has subsequently been shown to constitutively inhibit ERK1/2 activation [51], 
although a direct method was not resolved.  Additional studies revealed increased 
activation of signaling via both the serum response element (SRE) and the cAMP 
response element (CRE) [52].  The search for native agonists to this receptor has led to 
the proposal that it may be activated by sphingosylphosphorylcholine (SPC) [53], as well 
as glucose and some individual amino acids [54].  Further investigation revealed that 
while the previous molecules do have an impact on GPR4 signaling, its primary function 
was as a pH sensor that coupled to Gαs, Gαq/11, and Gα13 [55].  This was supported by the 
identification of specific histidine residues that undergo protonation when exposed acid 
conditions up to and including physiological pH [56]. 
 While this work does reveal some stimulation of cAMP, it did not meet criteria 
required to be considered constitutively active.  Inhibition of 3 µM Forskolin (-86%) did 
meet all criteria and would amount to the first evidence that this orphan receptor may 
couple to Gαi or other inhibitory mechanisms.   
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 It is worth noting in this first example that the use of the term constitutive for this 
receptor is somewhat argumentative.  This term is used to infer “agonist independent” 
signaling.  It is left to the individual researcher to decide if the multiple protonation steps 
required to induce an active conformation of this receptor constitutes “agonist” activity. 
 
4.4. GPR6 
Another member of the 3-6-12 family, GPR6 has been shown to have a high 
affinity for sphingosine-1-phospate as a potential ligand and to constitutively increase 
cAMP in its absence as well [48].  Further study of this potential agonist has resulted in 
relative agreement, but in one particular case also revealed a single incident of its 
signaling being sensitive to pertussis toxin [57].  Studies done in-vivo and in-vitro have 
also implicated this orphan as having an impact in stimulation of neurite outgrowth and 
counteracting myelin inhibition [58] as well as being capable of signaling from internal 
compartments after being internalized from the cell membrane [59]. 
 This work supports previous assertions that GPR6 constitutively stimulates cAMP 
dependent signaling compared to baseline (295%) but also reveals its potential to inhibit 
Forskolin stimulation of cAMP dependent signaling as well (-57%).  This would support 
the findings stated above regarding pertussis sensitivity, a toxin that acts to specifically 




The last member of the highly constitutively active “3-6-12 family”, GPR12 
behaves very similarly to its siblings with respect to elevating cAMP levels but it has 
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been found to have impacts on calcium mobilization as well [60].   It is upregulated in 
response to fluid sheer stress in vascular endothelial cells [61] and has a pertussis 
sensitive response to exposure of sphingosylphosphorylcholine (SPC) [62].  
 Results of this work agree that this receptor is capable stimulating (223%), and 
inhibiting (-48%) cAMP dependent signaling in a constitutive manner, although it would 
be the first to claim such inhibition is constitutive and not agonist dependent. 
 
4.6. GPR15 
GPR15 was first cloned in 1996 [63].  It has since been implicated in intestinal 
sensitivity to gp120, a small protein found in the blood of HIV positive patients.  
Evidence that it is capable of signaling via Gαi and Gαq pathways was found via pertussis 
sensitive [64], and phospholipase inhibition [65] after gp120 exposure respectively. It 
was suggested that high levels of expression of this orphan receptor may help target those 
cells for potential immune responses [66].   
 While this work supports these findings- with GPR4 showing strong inhibition of 
cAMP dependent signaling under both baseline (-79%) and 3 µM Forskolin stimulation  
(-66%), it is the first to reveal constitutive activity of this receptor.  
 
 
4.7. GPR17 VARIANT 3 
GPR17 is a putative uracil/cysteinyl-leukotrienes receptor that can signal via 
inhibition of cAMP and calcium mobilization [67].  It is expressed in neuronal cells in 
response to damage and to mediate local repair mechanisms [68].   The receptor is rather 
promiscuous and capable of signaling via Gαi/Gαs/Gαq pathways [69].  Inhibitory 
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signaling via Gαi has been additionally confirmed via luciferase and other methods [70], 
[71] with one study finding as high as 80% inhibition of forskolin stimulation in CHO 
cells, although they were not able to isolate the signaling to GPR17 specifically [72].   
 This work supports the assertion that GPR17 is a constitutively active orphan 
receptor with respect to Gαi activation with significant inhibition cAMP dependent 
signaling under baseline (-87%) and forskolin stimulated (-92%) conditions. 
 
4.8. GPR18 
The murine homolog of GPR18 was first isolated in 1996 [73]. A potential 
agonist for this orphan was proposed until 2006 when N-arachidonylglycine (NAGly) 
was shown to increase calcium concentration and inhibit forskolin induced cAMP 
production in CHO cells in a pertussis sensitive manner [74].  This orphan is known to be 
constitutively active in melanomas, acting as an apoptosis inhibitor [75].  It plays the 
reverse roll in macrophage apoptosis, signaling cell death [76].  Both of these rolls were 
mediated via Gαi pathways.  Work on alternate cannabinoid compounds as potential 
agonist showed differential activation of Gαq / Gαi signaling suggesting biased agonism 
in pathway selection [77]. 
 This work supports the assertion that GPR18 constitutively signals via the Gαi 
pathway, showing a reduction of baseline cAMP dependent signaling (-44%) and 





GPR19 was first mapped on a human chromosome in 1999 [78].  It is expressed 
in neuronal cells during mouse embryogenesis and plays its most significant role in early 
development [79].  Expression of this orphan is also increased in metastatic melanomas 
although its impact on the tumor cells is unknown [80].  It has been previously evaluated 
via a study that assumed constitutive signaling due to overexpression, where in it elevated 
calcium levels in the presence of a Gq/i chimeric [60].  This chimeric protein couples to 
receptors with an affinity for Gαi, but signals via calcium mobilization as a native Gαq.  
 This work did not reveal any significant cAMP dependent activity of GPR19 and 
it was scored as a “non-responder”.  The loss of statistical significance under forskolin 
stimulation was due to extreme variability of response (as shown in Figure 4.1).  This, 
coupled with the extreme significance of the “block” and “treatment-by-block” analysis 




GPR20 is a member of the G protein coupled receptors for which exceptionally 
little is known.  It was first cloned and mapped on a human chromosome in 1997 [81].  
And it constitutively activates Gαi in a pertussis sensitive manner [82].  
This work supports the above assertion with an inhibition of baseline signaling    
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Figure 4.1. Results of five experiments with GPR19.  The percent change of cAMP- 
dependent signaling in CHO-K1 cells transfected with CRE-Luciferase reporter vector 
and orphan G protein coupled receptors 19 (GPR19).  Activity was measured as relative 
light units (RLU) and normalized between experiments by dividing by the average of the 
3 µM Forskolin stimulated control within each plate.  This value was then divided by the 
control for each condition to obtain the fractional change, with a value of zero indicating 
no change from control levels. Criteria for constitutive activity in this study were 200% 
stimulation or -40% inhibition. Changes in basal cAMP dependent expression are 
indicated on the left under “Baseline”.  Changes in expression in the presence of 3 µM 
Forskolin (6 hour exposure) is indicated on the right under “3 uM Forsk”. Significant 
divergence from control expression is marked as calculated via Students T-test (n=4, * = 






GPR21 was first cloned in 1993 [83], and then mapped on a human chromosome 
in 1997 [81].  It was a member of the group studied under the assumption that over-
expression led to constitutive signaling.  This resulted in a mobilization of calcium 
indicative of a Gαq response [60].  Subsequent work has suggested it plays a role in 
weight and metabolism via reducing insulin sensitivity, with GPR21 knockout mice not 
getting obese under high caloric diets [84] [85].  
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This work suggests for the first time that GPR21 is constitutively active via 
cAMP dependent pathway; increasing baseline cAMP dependent expression by 421%. 
 
4.12. GPR22 
GPR22 was first cloned and mapped in 1997 [81].   Evidence exists that it may 
couple exclusively to Gαi therefore inhibiting cAMP, playing a role in the regulation of 
cardiac function [86].  It has been implicated as a risk factor for the development of 
osteoarthritis based on chromosomal location [87], but other studies have called that 
conclusion into question [88].  It has a significant role in axis formation and knockout of 
GPR22 leads to defective axis formation and changes in cilia structure within the 
Kupffer's vesicle of zebra fish [89].  These findings suggest it functions beyond simple 
cardiac regulation. 
 This work scored GPR22 as a “Non-Responder”- although the baseline results 
were varied enough to loose statistical significance.  This was primarily due to a single 
plate with highly divergent responses.  If this outlier is removed, the remaining four 
experiments would be show an inhibition of baseline signaling (-34%) and an inhibition 
of forskolin stimulated signaling (-46%).  These adjusted values would have a significant 
treatment factor (p < 0.01) and would meet criteria for Gαi activation in agreement with 
the previous studies above. 
 
4.13. GPR25 
GPR25 is another orphan receptor for which information is very limited.  It was 
discovered and mapped to chromosome 1 in 1997 [90] and its expression is regulated 
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during exposure to LDL particles within smooth muscles [45].  No mention of a pathway 
or mechanism for this result is explained. 
 This work is the first to suggest that GPR25 is a constitutively active orphan 
GPCR that acts to significantly inhibit cAMP levels under both baseline (-87%) and 
forskolin stimulated (-81%) conditions. 
 
4.14. GPR26 
GPR26 was first cloned and identified in 2000 [91], and then mapped in 2001 
[92]. It was able to elevate cAMP levels in a study that assumed overexpression would 
lead to constitutive activation [60].  It was found to be constitutively active in HEK293 
cells where it elevated cAMP levels [93]. Another study found that GPR26 is 
epigenetically silenced in human glioblastomas and was capable of increasing cAMP in 
HEK cells in-vitro [94].  And knockout of GPR26 reduced cAMP levels in central 
amygdala resulting in mice showing signs of severe depression [95].   
 This work agrees with the previous studies asserting the ability of GPR26 to 
stimulate cAMP dependent signaling under baseline conditions, although it did not meet 
criteria to be considered “constitutive” (only 170% increase).  It did meet criteria for 
constitutive activity via inhibition of forskolin stimulation (-57%) and this work is the 
first to suggest that GPR26 may also play a role in cellular metabolism via this pathway. 
 
4.15. GPR27 
GPR27 was first discovered in 1998 [96].  It is highly conserved between human, 
monkey, and rat homologs and may play a role in neural plasticity [97]. Overexpression 
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in 293T cells increases IP3 levels and siRNA knockout in MIN6 cells reduces IP3 
suggesting activation of the Gαq pathway [98].  No other studies referencing specific 
mechanism, or constitutive activity outside of the Gαq /IP3/Calcium pathway was found. 
 This work is the first to suggest that GPR27 may constitutively signal through the 
Gαi pathway due to high levels of inhibition under both baseline (-74%) and forskolin 
stimulated conditions (-68%). 
. 
4.16. GPR31 
GPR31 was first isolated in 1997 [99]. It has been suggested that the lipid 
molecule 12-(S)-hydroxy-5,6,10,14-eicosatetraenoic acid (HETE) may couple with this 
receptor [100], but no mention of which pathway is stimulated was suggested.  
 This work is the first to suggest that GPR31 may constitutively signal through the 
Gαi pathway due to high levels of inhibition under baseline (-74%) and forskolin 
stimulated conditions (-71%). 
 
4.17. GPR32 
GPR32 was first cloned in 1998 [101]. Its expression is regulated in smooth 
muscles during exposure to LDL cholesterol particles [45] and may respond to 
“resolvins”, lipid molecules that are part of inflammatory signaling [102] [103].  When 
triggered with these molecules it activates MapK and Nf-kB pathways [104] suggesting 
activation via the G12 family.  One study also found possible Gαq activation via calcium 
mobilization [105].  While some study has been done on the potential impact of GPR32 
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activity on inflammatory signaling, no work has been done to show if this receptor is 
constitutively active or signals via the Gαs / Gαi cAMP dependent pathways. 
This work is the first to suggest that GPR32 may constitutively signal through the 
Gαi pathway due to high levels of inhibition under baseline (-69%) and forskolin 
stimulated conditions (-71%). 
 
4.18. GPR34 
GPR34 was discovered in 1999 [106] and subsequently mapped in 2000 [107].  
Lysophosphatidyl-L-serine (LysoPS) may be an agonist, showing a dose dependent 
inhibition of forskolin-stimulated cAMP in GPR34 expressing CHO cells, and possibly 
playing a role in mast cell degranulation [108].  Subsequent studies showed that the 
specificity for LysoPS is dependent on the Serine residue to activate Gαi signaling [109] 
and that it may [110], or may not be the native ligand for the human ortholog [111].  It 
has also been suggested that GPR34 may play a role in gastric cancer cell proliferation 
and migration with knockout GPR34 cancer cell lines showing considerably lower 
measurements under both of those metrics [112].   
 This work scored GPR34 as a “Non-Responder”.  Unlike a few other members of 
this group, GPR34 did not show a sizable elevation or inhibition of cAMP dependent 
signaling in the majority of its experiments.  Removing one experiment that was a 
significant outlier, the remaining experiments can be seen in Figure 4.2 below.  This, 
along with the few orphans who behaved similarly- is the basis for the assertion made in 
this work that the constitutive activity found here-in is not due to simple over-expression, 
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Figure 4.2. “Non-Responder” GPR34 results with single outlier removed.  The percent  
change of cAMP-dependent signaling in CHO-K1 cells transfected with CRE-Luciferase 
reporter vector and orphan G protein coupled receptors 34 (GPR34).  Activity was 
measured as relative light units (RLU) and normalized between experiments by dividing 
by the average of the 3 µM Forskolin stimulated control within each plate.  This value 
was then divided by the control for each condition to obtain the fractional change, with a 
value of zero indicating no change from control levels. Criteria for constitutive activity in 
this study were 200% stimulation or -40% inhibition. Changes in basal cAMP dependent 
expression are indicated on the left under “Baseline”.  Changes in expression in the 
presence of 3 µM Forskolin (6 hour exposure) is indicated on the right under “3 uM 
Forsk”. Significant divergence from control expression is marked as calculated via 






GPR35 was discovered in 1998 [96].  Kynurenic acid was suggested as a potential 
ligand for the rat homolog in 2006.  Exposure to this ligand inhibited calcium channels in 
rat sympathetic neurons, and induced a calcium response when transfected with a 
chimeric Gαq/i discussed previously [113].  These effects were pertussis toxin sensitive, 
further indicating coupling with Gαi [114]. It has since been found to be rather non-
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specific in its agonist affinity [115] [116] including tyrphostin analogs [117], Aspirin 
metabolites [118], natural phenols [119]. 
This work scored GPR35 as a “Non-Responder”.  It did not meet study criteria for 
constitutive signaling.  This is in agreement with previous studies which have all been 
based on different agonist dependent experiments. These findings again support the 




GPR39 was first cloned in 1997 [120].  Signaling was originally thought to be due 
to a proposed agonist, obestatin, but was discovered to be caused instead by zinc ions 
[121].  Exposure to free zinc ions increased cytosolic calcium levels in cells transfected 
with GPR39 in a manner that was abolished by a PLC inhibitor [122]. HEK293T cells 
transfected with GPR39 showed constitutive activation of a SRE-Luciferase reporter 
which was not sensitive to obestatin [123].  These findings wound indicate that this 
receptor could signal through both Gαq and Gα12 pathways.  Evidence supporting this was 
found via disruption of the highly conserved di-sulfide bridges of this GPCR, diminishing 
agonist induced signaling via Gαq dependent calcium mobilization, but increasing 
constitutive SRE dependent signaling.  Disruption of a second di-sulfide bridge, unique to 
GPR39, caused the inverse effect- greatly increasing agonist affinity and potency while 
diminishing constitutive SRE signaling [124].  There was a single study that found 




 This work scored GPR39 as a “Non-Responder”: unable to reach study criteria to 
be considered constitutively active (-40%).  Even so, three out of four plates with GPR39 
did show a significant inhibition of cAMP dependent signaling that remains statistically 
significant (p < .01).  Removal of the single outlier would move this orphan into group A, 
significant inhibition of cAMP dependent signaling under both baseline (-63%) and 
forskolin stimulation (-57%).  If so- it would present the first evidence of potential 
constitutive activation via an inhibitory pathway and in the absence of its primary 
indicated agonist; zinc ions. 
 
4.21. GPR45 
GPR45 was discovered in 1999 [106] and is expressed highly in the brain [126]. 
This work adds the first evidence of potential Gαi activity via the strong suppression of 




GPR52 was first identified and cloned in 1999 [127].  It is well conserved among 
vertebrate species, couples to Gαs proteins and responds to reserpine, an antipsychotic 
drug.  In the presence of this agonist cAMP levels increased in a dose dependent manner 
but no evidence of constitutive basal signaling was found [128]. In the presence of a 
novel agonist, GPR52 was shown to inhibit D2 receptor signaling and activate D1 
signaling via cAMP accumulation [129]. 
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 This work agrees with previous findings indicating activation of cAMP dependent 
signaling but is the first to show constitutive activation under basal signaling, let alone to 
the degree measured here-in (850%). 
 
4.23. GPR55 
First identified and cloned in 1999 [127], GPR55 was originally proposed as a 
cannabinoid receptor [130]. Pathway analysis revealed its primary function under agonist 
stimulation was via calcium mobilization [131]. Subsequent identification of additional 
cannabinoid compounds, with special affinity for delta(9)-THC,  that elicited calcium 
mobilization solidified this as its primary mode of signaling [132].  This lead to 
subsequent screens for alternative agonists [133] and antagonists [134] but these were 
only watching the Gαq/calcium pathways.  Understandably for a receptor with such a 
large repertoire of suggested binding agents, the ability to recruit and signal via the Gαq 
pathway was determined to be highly agonist specific [135].  Additional information 
complicating the understanding of this “orphan” receptor’s signaling pathway was found 
in its ability to hetero-dimerize with other cannabinoid GPCRs, thus shifting their 
signaling to its pathway [136]. 
 This orphan receptor remains so in name only due to the lack of consensus on the 
primary endogenous ligand. Out of all of the research covered in this work, there was no 
mention of constitutive activity.  The ability to significantly inhibit both baseline (-80%) 
and forskolin stimulated (-78%) cAMP dependent gene expression as shown here-in is 




4.24. GPR57 VARIENT 1 
GPR57 was first mapped in 2000 [91].  It has been suggested that it plays a role in 
febrile seizures due to its location on chromosome 6 [137], and it is upregulated  for 
excretion in multiple types of human cancer cells lines [138]. 
 This work is the first to suggest a pathway of activity for this receptor, and to 
show it is capable of constitutively inhibiting baseline (-40%) and forskolin stimulated (-
44%) cAMP dependent gene expression. 
 
4.25. GPR61 
GPR61 was first identified in 2001 [139], and is expressed to a high degree in 
different areas of the brain [140].  It couples with Gαs constitutively and is dependent on 
the presence of the N-terminal 20 amino acids in order to maintain its activity, potentially 
acting as its own intra-molecular ligand [141]. Subsequent research suggested it plays a 
role in obesity [142] and Type 2 diabetes [143].  
 While this work does not agree with the assertion of constitutive Gαs coupling 
(157% increase did not meet thresholds for constitutive activity) it is the first to suggest 
that it may have an alternative role in the inhibition of cAMP via its suppression (-57%) 
of elevated cAMP levels due to forskolin stimulation. 
 
4.26. GPR62 
GPR62 was first discovered in 2001 and was found to be expressed highly in the 
brain [140].  Little else is known about this orphan receptor. 
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This work is the first to suggest it may be active physiologically via the 
constitutive inhibition of cAMP dependent signaling, shown by its ability to inhibit (-
64%) forskolin dependent expression.  The lack of inhibition under baseline conditions 
would suggest that it either couples to Gαs and Gαi as the M2 muscarinic receptor, or that 
its Gαi coupling is cAMP dependent. 
 
4.27. GPR63 VARIANT 2 
First identified in 2001 [140], it has been suggested that this orphan receptor binds 
to sphingosine 1-phosphate (S1P) causing an inhibition of cAMP via Gαi [144]. No other 
mention of pathway or constitutive activity was found. 
 This work scored this receptor as a “Non-Responder”, with no significant 
stimulation of baseline cAMP dependent signaling and the loss of a statistically 
significant treatment effect under forskolin stimulation.  This is further evidence that the 
scoring methodology used in this work is not due to simple over-expression of these 
receptors within this system. 
 
4.28. GPR65 
GPR65, also known as TDAG8, was first cloned in 1998 [145].  It is now known 
to be a “proton sensor” that stimulates cAMP under physiological pH and lower in-vitro 
[146]. Elevation of cAMP in cells expressing GPR65 enhanced cellular viability in mice 
[147]. And the proton sensor action of GPR65 may play a role in superoxide inhibition of 
neutrophils [148]. 
 This study scored GPR65 as a constitutively active Gαs signaler due to its 
stimulation of baseline cAMP dependent expression (317%) and its lack of any ability to 
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inhibit forskolin stimulation.  While conditions found within this work were controlled 
for pH between plates via the carbonate buffer and 5% CO2 injection during growth, as 
stated previously it is arguable that the signaling found here-in is not “constitutive”.   
 
4.29. GPR68 
GPR68, also known as OGR1, was first mapped in 1996 [149] and was 
subsequently shown to constitutively increase IP levels under physiological pH and lower 
[150].  Other studies found that this orphan was also able to stimulate the accumulation of 
cAMP, in addition to the accumulation of IP, suggesting coupling to both Gαs and Gαq, 
but only under conditions slightly below physiological pH [151].  Gαs coupling was 
found to be unlikely during further examination, as the cAMP production was abolished 
in the presence of a PLC-inhibitor, suggesting it was due to cross-talk and not direct 
stimulation of the Gαs protein itself  [152]. 
 This work disagrees with previous assertions of cAMP stimulation, scoring this 
orphan instead as a constitutive inhibitor of cAMP dependent signaling under baseline    
(-48%) and forskolin stimulated (-73%) conditions.  Previous studies did not examine the 
ability of this orphan to abolish artificially elevated cAMP levels stimulated via an 






GPR78 was first mapped in 2001 [92].  It was found to be constitutively active in 
HEK293 cells coupled to increase in cAMP as predicted in hidden Markov model 
method. For this reason, potential inhibition vs. Gαi was not assayed [93]. 
 This work is the first to suggest constitutive activation of Gαi via the inhibition    
(-73%) of forskolin stimulated cAMP dependent expression.  The lack of inhibition under 
baseline conditions agrees with either a competitive interaction of this orphan with a Gαs 
/ Gαi nature, such as the human M2 muscarinic receptor, or that coupling with Gαi in a 
constitutive manner may be cAMP dependent. 
 
4.31. GPR82 
First mapped in 2001 [92], GPR82 deficient mice had a lower body weight, 
triglyceride level, and increased insulin sensitivity with no difference in 
respiratory/metabolic rates [153]. 
 This work scored GPR82 as a “Non-Responder” in that it did not reach thresholds 
to be considered constitutively active.  Even so, the treatment effect was very statistically 
significant, along with the “block” and “treatment by block” measurements (p < .01 in all 
cases).  Examination of the individual experiments reveals why.  Elimination of one 
outlier experiment, where both conditions showed stimulation above the 200% cut-off, 
leaves the remainder as shown in Figure 4.3.  While there is usually only minor impact on 
baseline cAMP dependent signaling, there seems to be an intermittent phenotype that 
shows high levels of inhibition of forskolin stimulated cAMP dependent expression.  
Even with this removal, the average response still does not meet criteria for constitutive 
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activity (only -39% under forskolin stimulation, although still significant treatment effect, 
p < 0.01) it is worth noting that there may be something more to the story of this very 
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Figure 4.3. “Non-Responder” GPR82 results with single outlier removed.  The percent  
change of cAMP-dependent signaling in CHO-K1 cells transfected with CRE-Luciferase 
reporter vector and orphan G protein coupled receptors 82 (GPR82).  Activity was 
measured as relative light units (RLU) and normalized between experiments by dividing 
by the average of the 3 µM Forskolin stimulated control within each plate.  This value 
was then divided by the control for each condition to obtain the fractional change, with a 
value of zero indicating no change from control levels. Criteria for constitutive activity in 
this study were 200% stimulation or -40% inhibition. Changes in basal cAMP dependent 
expression are indicated on the left under “Baseline”.  Changes in expression in the 
presence of 3 µM Forskolin (6 hour exposure) is indicated on the right under “3 uM 
Forsk”. Significant divergence from control expression is marked as calculated via 








First cloned in 2000, its expression was induced by glucocorticoid exposure 
[154], and is highly expressed in the forebrain [155]. It may play a role in the control of 
feeding behavior, regulation of stress and emotional behavior, learning and memory, and 
drug reinforcement and reward [156]. Pathway analysis of this orphan GPCR in mice 
reveals basal Gαq activity without any change in cAMP levels, even in the presence of 
forskolin.  This same study also showed this orphan acts as a Zn(II) sensor via multiple 
extracellular histidine residues [157]. The N-terminal end of GPR83 acts as its own 
inverse-agonist, with deletion mutants increasing basal Gαq signaling via calcium 
mobilization but does not impact cAMP dependent signaling [158]. 
 While this work does not agree with previous findings in mice, CHO-K1 cells 
transfected with GPR83 shows significant and sizable inhibition of baseline (-78%) and 
forskolin stimulated (-70%) cAMP dependent signaling. This would be the first 
suggestion of such activity. 
 
4.33. GPR84 
First discovered in 2001[159], it has been suggested as a medium chain free fatty-
acid (FFA) receptor, acting via calcium mobilization and cAMP inhibition [160]. Impacts 
of FFA on metabolism, including consideration of GPR84 as a FFA receptor, has been 
reviewed twice in recent history [161], [162]. 
 This work agrees with previous work that GPR84 acts through Gαi inhibiting 
cAMP dependent signaling of baseline (-44%) and forskolin stimulated (-54%) 
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conditions.  It is arguable if this activity is truly “constitutive” or if it is responding to 
FFAs in the cell culture medium during the experiment. 
 
4.34. GPR85 
GPR85 is an orphan G protein coupled receptor expressed primarily in the brain 
[163], plays a role in neural plasticity and is highly conserved between human, monkey, 
and rat [97].  Over expression of this receptor in mice decreased brain size, and knock-
out mice showed increased brain size [164]. 
 This work scored GPR85 as a “Non-Responder”, with the baseline expression not 
even capable of holding statistical significant treatment effect.  Even so, examination of 
the experimental data (Figure 4.4) reveals a strong trend between two different responses- 
one that amounts to no effect among the first three experiments, and a significant 
inhibition of cAMP dependent signaling in later experiments.  What may have caused this 




Data mining of previous studies discovered GPR87 in 2001 [159].  
Lysophosphatidic acid (LPA) has been suggested as a potential agonist for GPR87, via 
activation of a G protein fusion eliciting a calcium response [165].  It is over-expressed in 
many cancer cells and knockdown of GPR87 has anti-proliferative affect [166].  This 
work scored GPR87 as a “Non-Responder”.  Along with others mentioned in this group, 
the response of GPR87 is further evidence that this work is not measuring activity due 
solely to the over-expression of the receptor.  This supports the claim that the criteria 
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used within this work as an effective means of measuring constitutive activity inherent in 
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Figure 4.4. “Non-Responder” GPR85 results with single outlier removed.  The percent  
change of cAMP-dependent signaling in CHO-K1 cells transfected with CRE-Luciferase 
reporter vector and orphan G protein coupled receptors 85 (GPR85).  Activity was 
measured as relative light units (RLU) and normalized between experiments by dividing 
by the average of the 3 µM Forskolin stimulated control within each plate.  This value 
was then divided by the control for each condition to obtain the fractional change, with a 
value of zero indicating no change from control levels. Criteria for constitutive activity in 
this study were 200% stimulation or -40% inhibition. Changes in basal cAMP dependent 
expression are indicated on the left under “Baseline”.  Changes in expression in the 
presence of 3 µM Forskolin (6 hour exposure) is indicated on the right under “3 uM 
Forsk”. Significant divergence from control expression is marked as calculated via 






First mapped in 2001 [92], GPR101 is matched to Gαs via hidden Markov model 
analysis and elevated CRE dependent luciferase expression in HEK293 cells, although no 
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test for forskolin inhibition was done [167].  It has also been linked to acromegaly due to 
single nucleotide polymorphism mutation [168]. 
 This study agrees with the implication of Gαs signaling, although it did not meet 
criteria for constitutive signaling, and is the first to show inhibition of forskolin 
stimulated expression (-68%). 
 
4.37. GPR119 
First identified in 2002 [169], GPR119 has been highly studied as a target for 
metabolic disorders including type 2 diabetes.  Its remaining classification as an orphan is 
due mainly to the ongoing search and disagreement as to its primary native agonist.  For 
example, Lysophosphatidylcholine (LPC) acts as a strong enhancer of rat pancreatic 
insulin secretion in response to high concentrations of glucose via the simulation of 
cAMP.  LPC also increases cAMP in mouse pancreatic cell lines in a dose dependent 
fashion. Exposure to siRNA specific to GPR119 blocked these effects [170]. 
Oleoylethanolamide and N-oleoyldopamine are potent agonists of GPR119, inducing 
intracellular cAMP accumulation in both pancreatic and gut enteroendocrine cells [171]. 
These suggested agonists were found to have differential effect on GPR119 pathway 
signaling preferentially activing cAMP or calcium mobilization [172].  GPR119 and its 
implications for the treatment of type 2 diabetes and related metabolic disorders was 
reviewed in 2009 [173], and again 2012 [174]. The search for potential agonists since has 
concentrated on finding activating molecules that do not cause severe desensitization 
during in-vivo studies [175].  Recent studies have noted constitutive activity of this 
receptor that is Gαs dependent [176,177], and is highly dependent on multiple 
extracellular residues [178]. 
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 This work scores GPR119 as a constitutive inhibitor of forskolin stimulated 
cAMP dependent signaling (-84%), but does not agree with recent findings indicating 
constitutive Gαs pathway activation.  It does not seem common among assumed Gαs 
constitutive signalers to test if they can inhibit an exogenous cAMP stimulation 
(forskolin). Given the nature of this orphan in regulation of cAMP dependent insulin 
release the potential that it may constitutively signal via inhibitory pathways would 
contribute to its homeostatic mechanism.  This could also be explained via differences in 
cell expression in CHO cells verses cells lines that natively express this orphan. 
 
4.38. GPR132 
GPR132, also known as G2A, has been suggested as a receptor for oxidized 
FFAs- with a potential role in lipid overload and oxidative stress via calcium 
mobilization [179]. It is also been suggested as a pH-sensor but is missing the Histidine 
residues of its relatives (GPR4, TDAG8) and did not significantly elevate IP or cAMP 
[146]. Further examination showed that it is not as sensitive to pH as its relatives, but 
may signal through Gαi / Gαq / Gαs, and Gα13 to influence Migration, and apoptosis 
[180]. Lysophosphatidyl-choline (LPC) binding to GPR132 can produce signaling via IP 
& cAMP, though only the cAMP response is dose dependent [181].  Activation by 9-
hydroxyoctadecadienoic acid (9-HODE) in CHO-K1 cells showed Ca mobilization, IP3 
increase, and inhibition of cAMP levels, suggesting activation of Gαi signaling pathways 
[182]. Lysophosphatidyl-serine acts as an agonist for GPR132 causing an increase in 
cAMP in macrophages and increased their ability to clear recruited neutrophils from 
areas of inflammation [183]. 
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 This work scores GPR132 as a strong inhibitor of baseline (-68%) and forskolin 
stimulated (-70%) cAMP dependent signaling.  This orphan is a highly studied G protein 
coupled receptor that only remains an orphan due to the disagreement over the primary 
native agonist coupled to its activation.  Most of its agonist-dependent action seems to be 
related to Gαq / Gαs signaling, the constitutive Gαi implicated within this work may be a 
new function in maintaining low levels of cAMP until stimulated by agonists. 
 
4.39. GPR150 
First discovered in 2005 [184], GPR150 is a possible candidate for tumor bio-
marker as it was upregulated in 4 out of 15 different cancer types via methylation of its 
promotor [185]. Structurally, it is related to gonadotropin releasing hormone receptors, 
although no agonist has been suggested [39]. 
 This work suggests for the first time that GPR150 is a strong constitutive inhibitor 
of baseline (-85%) and forskolin stimulated (-78%) cAMP dependent expression.  As 
seen in Figure 4.5, the treatment effect of GPR150 being present in CHO-K1 cells is 
significant and is similar to results seen in all members found in “Group A” in this work. 
 
4.40. GPR176 
GPR176 was first discovered in 1995 [186], and is regulated during smooth 
muscle cholesterol synthesis but there is no mention of a pathway [45]. 
 This work is the first to show that GPR176 is a strong constitutive inhibitor of 
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Figure 4.5. “Group A” GPR150 results.  The percent change of cAMP-dependent  
signaling in CHO-K1 cells transfected with CRE-Luciferase reporter vector and orphan G 
protein coupled receptors 150 (GPR150).  Activity was measured as relative light units 
(RLU) and normalized between experiments by dividing by the average of the 3 µM 
Forskolin stimulated control within each plate.  This value was then divided by the 
control for each condition to obtain the fractional change, with a value of zero indicating 
no change from control levels. Criteria for constitutive activity in this study were 200% 
stimulation or -40% inhibition. Changes in basal cAMP dependent expression are 
indicated on the left under “Baseline”.  Changes in expression in the presence of 3 µM 
Forskolin (6 hour exposure) is indicated on the right under “3 uM Forsk”. Significant 
divergence from control expression is marked as calculated via Students T-test (n=4,  * = 









 The following conclusions can be drawn from the data and analysis presented in 
this work: 
 Gene expression assays are a viable and meaningful characterization method for 
receptor signaling and can reveal promiscuity and constitutive activity of G 
protein coupled receptors.  
o This technique was able to characterize both wild-type and constitutively 
active versions of all five members of the Muscarinic GPCR family in 
agreement with canonical understanding.  
 This technique allowed for the experimental examination of 40 different orphan 
class-A G protein coupled receptors to screen for the prevalence of cAMP 
dependent constitutive signaling, revealing such activity in 75% of receptors 
studied. 
 Constitutive inhibition of cAMP dependent signaling was much more common 
than stimulation 
 Novel findings with respect to potential signaling pathways was found in 23 
orphans, and otherwise agrees with previous findings where signaling pathway 
has been examined.   
 Results of this work can be attributed to constitutive signaling and not simple over 
expression of receptors. 
o “Non-Responders” revealed patterns that suggest either a lack of 




 Constitutive signaling is an important physiological property a majority of the 
remaining orphan class-A GPCRs. 
o The search for inverse agonists may be the most effective approach to 
understanding their physiological roles as well as selecting targets for 
pharmacological intervention 
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